Panitumumab, Gemcitabine, and Carboplatin as Treatment for Women With Metastatic Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial-Reference-Cited by-同舟云学术

Panitumumab, Gemcitabine, and Carboplatin as Treatment for Women With Metastatic Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial

Published:2016-10 Issue:5 Volume:16 Page:349-355
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Yardley Denise A.,Ward Patrick J.,Daniel Brooke R.,Eakle Janice F.,Lamar Ruth E.,Lane Cassie M.,Hainsworth John D.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference37 articles.

1. Triple-negative breast cancer;Foulkes;N Engl J Med,2010

2. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma;Livasy;Mod Pathol,2006

3. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma;Nielsen;Clin Cancer Res,2004

4. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network;Lin;Cancer,2012

5. The TNT trial: a randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer;Tutt;San Antonio Breast Cancer Symposium,2014

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Treatment of Metastatic Triple‐Negative Breast Cancer: A Systematic Review;The Breast Journal;2024-01

2. Personalized Medicine in Clinical Management of Breast Cancer: Where Do We Stand?;Molecular Biomarkers for Cancer Diagnosis and Therapy;2024

3. The regulation of PTEN: Novel insights into functions as cancer biomarkers and therapeutic targets;Journal of Cellular Physiology;2023-06-18

4. Inhibition of ERK signaling for treatment of ERRα positive TNBC;PLOS ONE;2023-05-10

5. ‘Why is survival with triple negative breast cancer so low? insights and talking points from preclinical and clinical research’;Expert Opinion on Investigational Drugs;2022-12-02